What is Mirum Pharmaceuticals, Inc. (MIRM) stock price today?

Mirum Pharmaceuticals, Inc. (MIRM) is currently trading at $86.01, up 5.73% today.

What is MIRM P/E ratio?

Mirum Pharmaceuticals, Inc.'s P/E ratio is -5.70. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MIRM return on equity (ROE)?

Mirum Pharmaceuticals, Inc.'s return on equity (ROE) is -410.20%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Mirum Pharmaceuticals, Inc.'s market cap?

Mirum Pharmaceuticals, Inc. has a market capitalization of $5.24B.

NASDAQ · Biotechnology

Mirum Pharmaceuticals, Inc. (MIRM) Stock

$86.01 +5.73% NASDAQ: MIRM Healthcare

Valuation

Metric	Value
Price	$86.01
Market Cap	$5.24B
P/E Ratio	-5.70
P/B Ratio	-504.28
P/S Ratio	8.18
EPS (TTM)	$-13.60
52-Week High	$130.00
52-Week Low	$63.23
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-410.20%
ROA	-82.32%
ROCE	-13.09%
Gross Margin	81.39%
Operating Margin	-39.51%
Net Margin	-139.18%
Debt/Equity	-72.97
Current Ratio	2.09

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$19.0M	$77.0M	$186.0M	$337.0M	$521.0M
Operating Profit	$-173.0M	$-131.0M	$-109.0M	$-88.0M	$-22.0M
Net Profit	$-84.0M	$-136.0M	$-163.0M	$-88.0M	$-23.0M
EPS	$-2.77	$-4.02	$-4.00	$-1.85	$-0.47
Op Margin	-906.1%	-170.3%	-58.6%	-26.0%	-4.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$295.0M	$353.0M	$647.0M	$671.0M	$843.0M
Total Liabilities	$174.0M	$211.0M	$398.0M	$445.0M	$528.0M
Cash	$31.0M	$28.0M	$286.0M	$223.0M	$297.0M
Borrowings	$3.0M	$2.0M	$308.0M	$318.0M	$319.0M

Latest News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 13, 2026 Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Stocks To Watch: 14 Names Test And Tease New Buy Zones Investor's Business Daily · Jul 8, 2026 RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating MT Newswires · Jul 7, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-133.0M	$-120.0M	$-71.0M	$10.0M	$56.0M
Investing Cash Flow	$30.0M	$7.0M	$-127.0M	$-91.0M	$-25.0M
Financing Cash Flow	$67.0M	$2.0M	$-185.0M	$0	$0
Net Cash Flow	$-11.0M	$-3.0M	$158.0M	$-63.0M	$75.0M
Free Cash Flow	$-152.0M	$-120.0M	$-91.0M	$9.0M	$55.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-7.06
FCF Yield	-9.06%
Quick Ratio	2.74
Interest Coverage	-8.01
Return 1Y	36.02%
Return 3Y	265.31%
Return 5Y	454.61%

Ownership

Insiders Held1.39%

Institutions Held114.40%

Institutions Float Held116.01%

Institutional Holder	Shares	Report Date
Frazier Life Sciences Management, L.P.	7,679,684	2026-03-31
Janus Henderson Group PLC	6,945,813	2026-03-31
Blackrock Inc.	3,846,530	2026-03-31
Vanguard Capital Management LLC	2,414,776	2026-03-31
FMR, LLC	1,965,375	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AGIOAgios Pharmaceuticals, Inc.	$31.81	-0.34%	-4.54	$1.90B	0.00%
ALTAltimmune, Inc.	$2.61	+0.38%	-3.42	$507.58M	0.00%
ARCTArcturus Therapeutics Holdings Inc.	$13.74	+6.76%	-3.91	$390.53M	0.00%
ENTAEnanta Pharmaceuticals, Inc.	$12.50	+3.31%	-5.32	$363.48M	0.00%
MDGLMadrigal Pharmaceuticals, Inc.	$471.75	-1.08%	-39.10	$10.90B	0.00%

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is led by CEO Christopher Peetz, employs 418 people, headquartered in Foster City, US, publicly traded since 2019.

Mirum Pharmaceuticals, Inc. (MIRM) stock trades at $86.01 with a market capitalization of $5.24B. The stock is valued at a price-to-earnings (P/E) ratio of -5.70, price-to-book of -504.28, price-to-sales of 8.18. Over the past 52 weeks the stock has ranged between $63.23 and $130.00, and currently trades 33.8% below its 52-week high.

On profitability, Mirum Pharmaceuticals, Inc. generates a return on equity (ROE) of -410.20%, return on capital employed of -13.09%, an operating margin of -39.51%, a net profit margin of -139.18%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides